# Title

 Food and Drugs. PART 343â€”INTERNAL ANALGESIC, ANTIPYRETIC, AND ANTIRHEU-MATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE


# ID

 CFR-2018-title21-vol5.Pt. 343


# Structured Analysis Summary

| Type        | Values                                                                                                                                        |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['at least']                                                                                                                                  |
| Condition   | ['provided that', 'when', 'if', 'unless']                                                                                                     |
| Entities    | ['Scope', 'United States Pharmacopeia', 'Permitted', 'Food', 'Indications', 'Rheumatologic', 'Warnings', 'Dependence', 'Aspirin', 'Buffered'] |
| Date        | ['1998-10-23', '2018-05-13']                                                                                                                  |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                 |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------------|
| at least      | this chapter provided that the finished product contains at least 1.9 milliequivalents of acid-neutralizing capacity per 325 milligrams |
| at least      | this chapter provided that the finished product contains at least 1.9 milliequivalents of acid-neutralizing capacity per 325 milligrams |


## Condition

| Condition     | Context                                                                                                                                              |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------|
| if            | as safe and effective and is not misbranded if it meets each of the conditions in this                                                               |
| unless        | Regulations are to chapter I of title 21 unless  otherwise noted.                                                                                    |
| provided that | antacid ingredient(s) identified in &#167;&#8201;331.11 of this chapter provided that the finished product contains at least 1.9 milliequivalents    |
| provided that | antacid ingredient(s) identified in &#167;&#8201;331.11 of this chapter provided that the finished product contains at least 1.9 milliequivalents    |
| provided that | permitted in accordance with &#167;&#8201;331.10(a) of this chapter provided that the finished product meets the requirements of &#167;&#8201;331.10 |
| when          | exact language and exact format provided, but only when accompanied by the comprehensive prescribing information required in                         |


## Entities

| Entities                   | Context                                                                                                                                                                                                                                                                                                 |
|:---------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                                                                                                                                                                                                        |
| Scope                      | Scope .                                                                                                                                                                                                                                                                                                 |
| Rheumatologic              | Rheumatologic  drug.                                                                                                                                                                                                                                                                                    |
| United States Pharmacopeia | as measured by the procedure provided in the United States Pharmacopeia  23/National Formulary 18.                                                                                                                                                                                                      |
| Rheumatologic              | Rheumatologic  active ingredients.                                                                                                                                                                                                                                                                      |
| United States Pharmacopeia | as measured by the procedure provided in the United States Pharmacopeia  23/National Formulary 18.                                                                                                                                                                                                      |
| Permitted                  | Permitted  combinations of active ingredients for cardiovascular-rheumatologic use.                                                                                                                                                                                                                     |
| United States Pharmacopeia | (These products must meet  United States Pharmacopeia (USP) standards for dissolution or drug release in                                                                                                                                                                                                |
| Indications                | &#8220;Description,&#8221; &#8220;Clinical Pharmacology,&#8221; &#8220;Clinical Studies,&#8221; &#8220;Animal Toxicology,&#8221; &#8220; Indications and Usage,&#8221; &#8220;Contraindications,&#8221; &#8220;Warnings,&#8221; &#8220;Precautions,&#8221; &#8220;Adverse Reactions,&#8221; &#8220;Drug |
| Warnings                   | Studies,&#8221; &#8220;Animal Toxicology,&#8221; &#8220;Indications and Usage,&#8221; &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; &#8220;Precautions,&#8221; &#8220;Adverse Reactions,&#8221; &#8220;Drug Abuse and Dependence,&#8221;                                                   |
| Dependence                 | &#8220;Contraindications,&#8221; &#8220;Warnings,&#8221; &#8220;Precautions,&#8221; &#8220;Adverse Reactions,&#8221; &#8220;Drug Abuse and Dependence ,&#8221; &#8220;Overdosage,&#8221; &#8220;Dosage and Administration,&#8221; and &#8220;How Supplied&#8221;                                        |
| Aspirin                    | Aspirin capsules must meet the dissolution standard for aspirin                                                                                                                                                                                                                                         |
| United States Pharmacopeia | standard for aspirin capsules as contained in the United States Pharmacopeia  (USP) 23 at page 132.                                                                                                                                                                                                     |
| Aspirin                    | Aspirin delayed-release capsules and aspirin delayed-release tablets must meet                                                                                                                                                                                                                          |
| Aspirin                    | Aspirin tablets must meet the dissolution standard for aspirin                                                                                                                                                                                                                                          |
| Aspirin                    | Aspirin in combination with alumina and magnesia in a                                                                                                                                                                                                                                                   |
| Aspirin                    | Aspirin in combination with alumina, and magnesium oxide in                                                                                                                                                                                                                                             |
| Aspirin                    | Aspirin effervescent tablets for oral solution must meet the                                                                                                                                                                                                                                            |
| Buffered                   | Buffered aspirin tablets must meet the dissolution standard for                                                                                                                                                                                                                                         |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-05-13 | The following combinations are permitted: Aspirin identified in &#167;&#167;&#8201;343.12 and 343.13 may be combined with any antacid ingredient identified in &#167;&#8201;331.11 of this chapter or any combination of antacids permitted in accordance with &#167;&#8201;331.10(a) of this chapter provided that the finished product meets the requirements of &#167;&#8201;331.10 of this chapter and is marketed in a form intended for ingestion as a solution.                                                                                                                                                                                         |
| 1998-10-23 | (1) The labeling contains the following prescribing information under the heading &#8220;Comprehensive Prescribing Information&#8221; and the subheadings &#8220;Description,&#8221; &#8220;Clinical Pharmacology,&#8221; &#8220;Clinical Studies,&#8221; &#8220;Animal Toxicology,&#8221; &#8220;Indications and Usage,&#8221; &#8220;Contraindications,&#8221; &#8220;Warnings,&#8221; &#8220;Precautions,&#8221; &#8220;Adverse Reactions,&#8221; &#8220;Drug Abuse and Dependence,&#8221; &#8220;Overdosage,&#8221; &#8220;Dosage and Administration,&#8221; and &#8220;How Supplied&#8221; in the exact language and the exact order provided as follows: |
|            |               REV: October 23, 1998.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |


